Eli Lilly’s Weight Loss Pill Could Transform Obesity Treatment
Written by Site Hub on April 21, 2025
Eli Lilly announced promising results for orforglipron, a once-daily weight-loss pill that helped patients with diabetes lose up to 8% of their body weight in trials. The GLP-1 drug, which avoids injections like Wegovy and Zepbound, could reshape the obesity treatment market. Side effects are similar to injectable options. With FDA approval expected in late 2026, orforglipron could become a blockbuster medication. Analysts anticipate high demand and pricing under $1,000/month, with Lilly stockpiling inventory ahead of release.
Advertisements
Source: NYTimes
WDKX Holiday Stream